ACHN News and Press, Achison Inc Cl A From 12/19/19

BLUE BELL, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that its shareholders have appr...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watch t...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

– 2.4 g/dL mean increase in hemoglobin at 24 weeks – – Reduction in blood transfusions from 34 to 1; and improvements in markers of hemolysis – -  Completed End of Phase 2 Meeting; Phase 3 Trial Initiation in early 2020 - BLUE BELL, Pa., Dec....

Topline data from an initial six-subject cohort in an open-label, single-arm  Phase 2 clinical trial evaluating Regeneron Pharmaceuticals' (NASDAQ: REGN ) pozelimab (REGN3918) in patients with paroxysmal nocturnal hemoglobinuria (PNH) showed a positive effect. More news on: Regene...

NEW YORK , Nov. 22, 2019 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City , is investigating potential claims involving the directors and officers regarding possible breaches of fiduciary duties and other violations of law rel...

The European Medicines Agency (EMA) has granted access to Achillion Pharmaceuticals (NASDAQ: ACHN ) to support through the PRIME (PRIority MEdicines) program for danicopan (ACH-4471) in the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in patients who are not adequately responding...

BLUE BELL, Pa., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the European Medicines Age...

BLUE BELL, Pa., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the U.S. Food and Drug Adm...

BioCryst (NASDAQ: BCRX ) has reported promising results from the phase 1 trial which is currently being carried out on BCX9930 to inhibit the alternative pathway of complement system. The trial is being carried out on 72 healthy volunteers and has resulted in a continuous suppression of mo...